AstraZeneca Plc and Daiichi Sankyo Co. announced that their cancer treatment, Enhertu, has delayed the growth of a common type of breast cancer by more than a year in a large late-stage trial. This development offers new hope for patients suffering from this aggressive form of the disease.
Key Findings
-
Effectiveness of Enhertu:
- When used as an initial treatment, Enhertu reduced the risk of worsening or death from HER2-positive breast cancer within 18 months by 34% compared to chemotherapy alone.
- The median time for cancer progression was approximately 11 months with Enhertu, compared to about 6 months with chemotherapy.
-
Patient Impact:
- David Fredrickson, executive vice president of AstraZeneca’s oncology business unit, highlighted that one in three patients starting treatment for this type of cancer cannot receive a second therapy due to health deterioration or death. He expressed optimism that Enhertu could significantly improve these outcomes.
Current Approvals and Mechanism
- Enhertu is already approved as an initial treatment for HER2-positive stomach and esophageal cancers.
- The drug works by targeting HER2 receptors, which are proteins found on certain tumor types.
Related Developments in Cancer Treatments
-
Pfizer Inc.’s Braftovi:
- This pill has doubled survival time for patients with an aggressive form of colorectal cancer compared to standard treatment in late-stage trials.
- It targets the BRAF V600E mutation, which is present in 10% to 15% of colorectal cancer patients. The survival rate for these patients is notably low, with just over half living five years post-diagnosis.
-
Gilead Sciences Inc.’s Trodelvy:
- Trodelvy has shown promising results as an initial treatment in combination with Merck & Co.’s Keytruda for triple-negative breast cancers (TNBC), reducing the risk of disease worsening by 35%.
-
Merck & Co.:
- Recently withdrew its US application for a treatment after it failed a key test.
-
Amgen Inc.’s Imdeltyra:
- This drug has been shown to reduce the risk of death among small-cell lung cancer patients whose disease worsened after initial chemotherapy, according to data from a late-stage trial.
These advancements in cancer treatment highlight the ongoing efforts to improve patient outcomes and provide new therapeutic options for aggressive cancer types.
I’m Mark W. Lamplugh Jr., a visionary Chief Executive Officer, Board Member, and best-selling Author with over 25 years of experience driving significant revenue growth and optimizing ROI across the healthcare, wellness, and media industries. Throughout my career, I’ve consistently transformed underperforming operations into thriving ventures by building top-tier marketing organizations, implementing data-driven strategies, and leading transformational change. My empathetic, collaborative, and adaptable leadership style has allowed me to cultivate inclusive cultures of innovation, develop and retain top talent, and forge strong partnerships that fuel organizational success.
Adept in executive leadership, strategic business planning, and brand and marketing strategy, I have a proven track record of boosting annual revenues—achieving up to $1.3B in oncology over three years and generating $360M in mental health initiatives. My approach combines strategic vision with hands-on execution, as evidenced by my success in launching innovative facilities, expanding services for addiction and mental health care, and enhancing organizational brand visibility. As author of “The AI Marketing Playbook,” I contribute thought leadership on the integration of artificial intelligence in marketing, a role that showcases my commitment to staying at the forefront of industry innovation.
I also bring my insights and expertise to a broad audience as the host of cable tv & global streaming of “Street Level Marketing Show,” while my writing has been featured in major publications such as Entrepreneur, Business.com, The Startup, and Kivo Daily. Whether I’m implementing targeted digital marketing campaigns that engage over a million individuals monthly or overseeing multi-million dollar budgets to maximize return on investment, I approach every challenge with a combination of strategic planning, creative problem-solving, and unwavering dedication. Above all, I am passionate about expanding access to high-quality addiction and mental health care through innovative solutions that drive both patient outcomes and organizational growth.
Mark serves on the board of One World for Life, National Fire Heritage Center, and the Institute for Responder Wellness.
Mark (https://marklamplugh.com) is one of the top marketing executives in the United States and has revolutionized how companies reach potential clients thru influence, SEO, social, PR, and traditional marketing. His expertise in Marketing, Social Media, Digital Marketing, and Public Relations has generated millions of dollars in revenue for several national companies. Mark documents many of his techniques in his book “Beginners Guide to Social & Digital Media.” and “Marketing Playbook for Social Media,” which was named the top 100 social media marketing books of all time by Book Authority. He’s also a professional advocate for the behavioral and mental health of firefighters and other first responders. Marks articles have been published in Better Marketing, Startup Magazine, Social Media Today, Kivo Daily, Biz Catalyst 360, Fire Engineering, Firehouse Magazine, and several others.
One of his companies, niches, are marketing products and services to the public safety industry and their employees, specifically mental & behavioral health services. He can be reached for comment at ceo@influencemediasolutions.com
23,000 #1 Connections, 40,000,000 US B2B Contacts and 300,000,000 B2b/B2C email contacts as well as 1,000,000+ monthly social media reach. https://marklamplugh.com
